Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy

European Urology

Volumn 56, Issue 3, 2009, Pages 430-442

  van Rhijn, Bas W G ^a   Burger, Maximilian ^b   Lotan, Yair ^c   Solsona, Eduardo ^d   Stief, Christian G ^e   Sylvester, Richard J ^f   Witjes, J Alfred ^g   Zlotta, Alexandre R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e UNIVERSITY OF MUNICH   (Germany)

^f EORTC DATA CENTER   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCG; Bladder cancer; Cystectomy; Cystoscopy; Epidemiology; Grade; Progression; Recurrence; Stage; Treatment

Indexed keywords

APAZIQUONE; BCG VACCINE; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; OFLOXACIN;

BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CYSTECTOMY; CYSTOSCOPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REOPERATION; REVIEW; TRANSURETHRAL RESECTION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; DISEASE PROGRESSION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 67651092245     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.06.028     Document Type: Review

References (141)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 1.0. International Agency for Research on Cancer Web site. http://www-dep.iarc.fr.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Colombel M., Soloway M., Akaza H., et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 7 (2008) 618-626
4. Wu X., Ros M.M., Gu J., and Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 102 (2008) 1207-1215
5. Zeegers M.P., Tan F.E., Dorant E., and van den Brandt P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89 (2000) 630-639
6. Murta-Nascimento C., Schmitz-Dräger B.J., Zeegers M.P., et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 25 (2007) 285-295
7. Kiemeney L.A., Thorlacius S., Sulem P., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40 (2008) 1307-1312
8. Aben K.K., Witjes J.A., Schoenberg M.P., Hulsbergen-van de Kaa C., Verbeek A.L., and Kiemeney L.A. Familial aggregation of urothelial cell carcinoma. Int J Cancer 98 (2002) 274-278
9. Kaldor J.M., Day N.E., Kittelmann B., et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 63 (1995) 1-6
10. Nieder A.M., Porter M.P., and Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 180 (2008) 2005-2009
11. García-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
12. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
13. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 Suppl 6A (2005) 4-34
14. Kiemeney L.A., Witjes J.A., Verbeek A.L., Heijbroek R.P., and Debruyne F.M. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 67 (1993) 806-812
15. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
16. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
17. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer. Pharmacoeconomics 21 (2003) 1315-1330
18. Riley G.F., Potosky A.L., Lubitz J.D., and Kessler L.G. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 (1995) 828-841
19. Ploeg M., Aben K.K., and Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 27 (2009) 289-293
20. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
21. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A (1995) 1840-1846
22. Kurth K.-H., and Sylvester R.J. Prognostic factors in non-muscle-invasive bladder tumors: I. Clinical prognostic factors: a review of the experience of the EORTC Genito-Urinary group II: biologic prognostic markers. Eur Urol Suppl 6 (2007) 789-799
23. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., Algaba F., and Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164 (2000) 680-684
24. Zieger K., Wolf H., Olsen P.R., and Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 85 (2000) 824-828
25. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
26. Sylvester R.J. Natural history, recurrence and progression in superficial bladder cancer. TSW Urology 1 Suppl 2 (2006) 15-23
27. Shariat S.F., Zippe C., Lüdecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173 (2005) 1518-1525
28. Shariat S.F., Margulis V., Lotan Y., Montorsi F., and Karakiewicz P.I. Nomograms for bladder cancer. Eur Urol 54 (2008) 41-53
29. Grimm M.-O., Steinhoff Ch., Simon X., Spiegelhalder P., Ackermann R., and Vögeli T.A. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170 (2003) 433-437
30. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
31. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
32. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73
33. Lee C.S.D., Yoon C.Y., and Witjes J.A. The past, present, and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int 102 (2008) 1228-1233
34. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., Marberger M., and Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
35. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007) 260-264
36. Daniltschenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
37. Denzinger S., Burger M., Walter B., et al. Clinically relevant risk of reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid induced fluorescence diagnosis: 8-years results of prospective randomized study. Urology 69 (2007) 675-679
38. Karl A., Tritschler S., Stanislaus P., et al. Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?. BJU Int 103 (2009) 484-487
39. Ray E.R., Chatterton K., Khan M.S., Thomas K., Chandra A., and O'Brien T.S. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology. BJU Int 103 (2009) 1363-1367
40. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147
41. Denzinger S., Wieland W.F., Otto W., Filbeck T., Knuechel R., and Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 101 (2008) 566-569
42. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160 (1998) 645-659
43. Karam J.A., Shariat S.F., Hsieh J.T., and Knowles M.A. Genomics: a preview of genomic medicine. BJU Int 102 (2008) 1221-1227
44. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese. Carcinogenesis 27 (2006) 361-373
45. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912-1921
46. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
47. Burger M., van der Aa M.N.M., van Oers J.M.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54 (2008) 835-844
48. Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
49. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. In: International Histological Classification of Tumours. No. 10. Geneva, Switzerland: World Health Organization; 1973. p. 21-31.
50. Ooms E.C., Anderson W.A., Alons C.L., Boon M.E., and Veldhuizen R.W. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14 (1983) 140-143
51. Tosoni I., Wagner U., Sauter G., et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 85 (2000) 48-53
52. Bol M.G., Baak J.P., Buhr-Wildhagen S., et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169 (2003) 1291-1294
53. Witjes J.A., Moonen P.M., and van der Heijden A.G. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology 67 (2006) 751-755
54. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22 (1998) 1435-1448
55. Eble J., Sauter G., Epstein J., and Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs (2004), IARC Press, Lyon, France
56. Lopez-Beltran A., and Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46 (2004) 170-176
57. MacLennan G.T., Kirkali Z., and Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51 (2007) 889-898
58. Hofmann T., Knüchel-Clarke R., Hartmann A., et al. Clinical implications of the 2004 WHO histological classification on non-invasive tumours of the urinary bladder. EAU-EBU Update Series 4 (2006) 83-95
59. Samaratunga H., Makarov D.V., and Epstein J.I. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 60 (2002) 315-319
60. Yin H., and Leong A.S. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 121 (2004) 679-687
61. Harnden P. A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change?. BJU Int 99 (2006) 723-725
62. Younes M., Sussman J., and True L.D. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66 (1990) 543-548
63. Holmang S., Hedelin H., Anderstrom C., Holmberg E., and Johansson S.L. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 157 (1997) 800-803
64. Smits G., Schaafsma E., Kiemeney L., Caris C., Debruyne F., and Witjes J.A. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 52 (1998) 1009-1013
65. Hasui Y., Osada Y., Kitada S., and Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 43 (1994) 782-786
66. Angulo J.C., Lopez J.I., Grignon D.J., and Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 45 (1995) 47-53
67. Orsola A., Trias I., Raventós C.X., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48 (2005) 231-238
68. Kondylis F.I., Demirci S., Ladaga L., Kolm P., and Schellhammer P.F. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 163 (2000) 1120-1123
69. Cheng L., Weaver A.L., Neumann R.M., Scherer B.G., and Bostwick D.G. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal. Cancer 86 (1999) 1035-1043
70. Cheng L., Neumann R.M., Weaver A.L., Spotts B.E., and Bostwick D.G. Predicting cancer progression in patient with T1 bladder carcinoma. J Clin Oncol 17 (1999) 3182-3187
71. van der Aa M.N., van Leenders G.J., Steyerberg E.W., et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 36 (2005) 981-986
72. Sedelaar J.P.M., and Witjes J.A. Technique of TUR of bladder tumours: value of repeat TUR and random biopsies. EAU-EBU Update Series 5 (2007) 139-144
73. Herr H.W., and Donat S.M. Quality control in transurethral resection of bladder tumours. BJU Int 102 (2008) 1242-1246
74. Zlotta A.R. When and how to treat superficial and muscle-invasive bladder cancer. Eur Urol 52 (2007) 1554-1557
75. Jakse G., Algaba F., Malmström P.-U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
76. Miladi M., Peyromaure M., Zerbib M., Saïghi D., and Debré B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43 (2003) 241-245
77. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol 165 (2001) 808-810
78. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 (2007) 75-79
79. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174 (2005) 2134-2137
80. Divrik R.T., Yildirim U., Zorlu F., and Özen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175 (2006) 1641-1644
81. Solsona E., Iborra I., Ricos J.V., Monros J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161 (1999) 1120-1123
82. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
83. Berrum-Svennung I., Granfors T., Jahnson S., Boman H., and Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179 (2008) 101-105
84. Gudjónsson S., Adell L., Merdasa F., et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55 (2009) 773-780
85. Lamm D., Colombel M., Persad R., et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 7 (2008) 651-666
86. Witjes J.A., and Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53 (2008) 45-52
87. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13 (1995) 1404-1408
88. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1941
89. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
90. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
91. Sylvester R.J., Oosterlinck W., and Witjes J.A. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53 (2008) 709-719
92. Hendricksen K., Witjes W.P.J., Idema J.G., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53 (2008) 984-991
93. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
94. Böhle A., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-687
95. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-91
96. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
97. Herr H.W. Is maintenance bacillus Calmette-Guérin really necessary?. Eur Urol 54 (2008) 971-973
98. Zlotta A.R., Drowart A., Van Vooren J.P., et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 157 (1997) 492-498
99. Huang G.J., Hamilton A.S., Lo M., Stein J.P., and Penson D.F. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol 180 (2008) 520-524
100. Martinez-Pineiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
101. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
102. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
103. van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta, T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 429-434
104. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 423-428
105. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
106. Au J.L., Baladament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
107. Hendricksen K., and Witjes J.A. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 16 (2006) 361-366
108. van der Heijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349-1353
109. Colombo R., Da Pozzo L.F., Salonia A., et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21 (2003) 4270-4276
110. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46 (2004) 65-72
111. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170 (2003) 777-782
112. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51
113. Stein J.P., and Penson D.F. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 102 (2008) 270-275
114. Cookson M.S., Herr H.W., Zhang Z.F., Soloway S., Sogani P.C., and Fair W.R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
115. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177 (2007) 1283-1286
116. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175 (2006) 881-885
117. Kunju L.P., You L., Zhang Y., Daignault S., Montie J.E., and Lee C.T. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180 (2008) 1928-1932
118. Andius P., Johansson S.L., and Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 70 (2007) 758-762
119. Masood S., Sriprasad S., Palmer J.H., and Mufti G.R. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36 (2004) 41-44
120. Denzinger S., Otto W., Fritsche H.M., et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 14 (2007) 995-999
121. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
122. Griffiths T.R., Charlton M., Neal D.E., and Powell P.H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167 (2002) 2408-2412
123. Davis J.W., Sheth S.I., Doviak M.J., and Schellhammer P.F. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167 (2002) 494-500
124. Patard J.-J., Rodriguez A., Leray E., Rioux-Leclercq N., Guillé F., and Lobel B. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41 (2002) 635-642
125. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
126. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
127. Gupta A., Lotan Y., Bastian P.J., et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71 (2008) 302-307
128. Schrier B.P.h., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45 (2004) 292-296
129. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
130. Solsona E., Iborra I., Rubio J., Casanova J., and Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 94 (2004) 1258-1262
131. Stöckle M., Alken P., Engelmann U., Jacobi G.H., Riedmiller H., and Hohenfellner R. Radical cystectomy - often too late?. Eur Urol 13 (1987) 361-367
132. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
133. van der Meijden A.P.M., Sylvester R., Oosterlinck W., et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48 (2005) 363-371
134. Borhan A., Reeder J.E., O'Connell M.J., et al. Grade progression and regression in recurrent urothelial cancer. J Urol 169 (2003) 2106-2109
135. Soloway M., Bruck D.S., and Kim S.S. Expectant management of small recurrent, non-invasive papillary bladder tumours. J Urol 170 (2003) 438-441
136. Gofrit O.N., Pode D., Lazar A., Katz R., and Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006) 303-307
137. Holmang S., and Johansson S.L. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 167 (2002) 1634-1637
138. Öge O., Erdem E., Atsü N., Ahin A., and Özen H. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol 37 (2000) 271-274
139. Mariappan P., and Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173 (2005) 1108-1111
140. Mariappan P., Smith G., Lamb A.D., Grigor K.M., and Tolley D.A. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol 177 (2007) 867-875
141. van Rhijn B.W.G., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748